Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Daré Bioscience, Inc. (NASDAQ: DARE) announced the initiation of a Phase 1 clinical study for its Sildenafil Cream, a potential treatment for female sexual arousal disorder (FSAD). The study aims to assess the pharmacodynamic and pharmacokinetic properties of the cream using thermography, with the goal of collecting quantitative data to complement patient-reported outcomes from the ongoing Phase 2b RESPOND study. This innovative cream formulation is designed to increase blood flow to genital tissues, addressing issues similar to erectile dysfunction in men. Approximately 15 women will be enrolled, and completion is planned for 2023. Topline data for the Phase 2b study is anticipated in Q2 2023, providing critical insights into the product's efficacy.